Skip to main content


Intravitreal injection linked to substantial temporary blood pressure increase


Patients undergoing intravitreal injections with anti–vascular endothelial growth factor agents can experience substantial transient increases in systolic blood pressure, Swiss researchers report.

11-04-2019 | Ophthalmology | News | Article

Aqueous humour cytokine levels predict anti-VEGF response in DME

Decreased cytokine concentrations in the aqueous humour are associated with a response to treatment with anti-vascular endothelial growth factor agents in patients with diabetic macular oedema, study data show.

04-04-2019 | Ophthalmology | News | Article

Port Delivery System reduces neovascular AMD treatment burden

The Port Delivery System with ranibizumab has the potential to reduce the burden of treatment for patients with neovascular age-related macular degeneration, suggest findings from the phase II Ladder trial.

28-03-2019 | Ophthalmology | News | Article

Dual targeting with faricimab benefits patients with diabetic macular oedema

Treatment with faricimab, a bispecific antibody that targets angiopoietin-2 and vascular endothelial growth factor-A, significantly improves visual acuity versus ranibizumab in patients with diabetic macular oedema, research shows.

21-03-2019 | Ophthalmology | News | Article

CD11b-positive monocytes could help guide anti-VEGF treatment in CNV diseases

Measuring CD11b-positive monocytes could help estimate how many anti-vascular endothelial growth factor injections a patient with neovascular age-related macular degeneration or polypoidal choroidal vasculopathy might need, study findings suggest.

Twitter Icon Follow medwireNews

Click here
image credits